Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $13.90 and traded as low as $10.38. Mesoblast shares last traded at $10.51, with a volume of 174,166 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Get Our Latest Report on MESO
Mesoblast Stock Up 0.8%
The company's 50 day moving average price is $11.20 and its 200-day moving average price is $13.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after acquiring an additional 272,595 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Mesoblast during the 1st quarter valued at $3,209,000. Oaktree Capital Management LP purchased a new stake in Mesoblast during the 4th quarter worth about $3,556,000. GAMMA Investing LLC boosted its stake in Mesoblast by 1,174.2% in the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock worth $1,067,000 after purchasing an additional 78,802 shares during the period. Finally, Summit X LLC boosted its stake in Mesoblast by 36.0% in the 1st quarter. Summit X LLC now owns 198,163 shares of the company's stock worth $2,473,000 after purchasing an additional 52,508 shares during the period. Institutional investors own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Recommended Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
